Table. 1.

Characteristics of studies included in the systematic review and meta-analysis

Study Country Design Data collection period Transplant type Sample size Severity of COVID-19 Remdesivir No remdesivir COVID-19 vaccination rate (%)a) Reported outcomes Treatment protocol Follow-up
(day)
No. of patients Mean age (yr) No. of patients Mean age (yr)
Cacho et al. (2022) [16] Spain RS Nov 2021–Feb 2022 Kidney 98 MS 57 59 41 55 98 Death, hospitalization, oxygen therapy 2 or 4 30
Colaneri et al. (2022) [23] Italy RS Dec 2021–Feb 2022 Kidney, heart, lung, liver 24 Moderate 7 60 17 55 100 Death, hospitalization, ICU admission 3 28
Elec et al. (2022) [24] Romania RS Mar 2020–May 2021 Kidney 165 MC 35 53 127 49 NA Death, ICU admission, MV, oxygen therapy 5 NA
Fesu et al. (2022) [17] Hungary RS Sep 2020–May 2021 NA 25 NA 15 55 10 49 NA Oxygen therapy NA 60
Razia et al. (2023) [25] USA RS Mar 2020–Aug 2022 Lung 54 MM 25 64 29 68 NA Death, hospitalization, ICU admission, MV NA 60
Solera et al. (2023) [18] Canada RS Apr–May 2022 Kidney, heart, lung, liver, other 192 MM 86 52 106 54 90 Death, ICU admission, MV, oxygen therapy 3 30
Villamarín et al. (2022) [19] Spain RS Jan–Apr 2022 Kidney 16 Mild 7 39 9 49 86 Death, hospitalization, ICU admission 3 NA

COVID-19, coronavirus disease 2019; RS, retrospective study; MS, mild to severe; ICU, intensive care unit; MC, moderate to critical; NA, not acquired; MV, mechanical ventilation; MM, mild to moderate.

a)COVID-19 vaccination ≥1 dose.

Clin Transplant Res 2024;38:212~221 https://doi.org/10.4285/ctr.24.0031